CN113495069B - 一种总胆固醇检测试剂及检测芯片 - Google Patents
一种总胆固醇检测试剂及检测芯片 Download PDFInfo
- Publication number
- CN113495069B CN113495069B CN202110420447.4A CN202110420447A CN113495069B CN 113495069 B CN113495069 B CN 113495069B CN 202110420447 A CN202110420447 A CN 202110420447A CN 113495069 B CN113495069 B CN 113495069B
- Authority
- CN
- China
- Prior art keywords
- reagent
- detection
- total cholesterol
- cholesterol
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 190
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 115
- 238000001514 detection method Methods 0.000 title claims abstract description 106
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 90
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 17
- 108010023417 cholesterol dehydrogenase Proteins 0.000 claims abstract description 17
- 229950006238 nadide Drugs 0.000 claims abstract description 17
- 108010085346 steroid delta-isomerase Proteins 0.000 claims abstract description 17
- 108010055297 Sterol Esterase Proteins 0.000 claims abstract description 12
- 102000000019 Sterol Esterase Human genes 0.000 claims abstract description 12
- 210000002966 serum Anatomy 0.000 claims description 32
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- 150000004985 diamines Chemical class 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 9
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 9
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 7
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 7
- 229960000367 inositol Drugs 0.000 claims description 7
- 239000008188 pellet Substances 0.000 claims description 7
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920001363 Polidocanol Polymers 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- ONJQDTZCDSESIW-UHFFFAOYSA-N polidocanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO ONJQDTZCDSESIW-UHFFFAOYSA-N 0.000 claims description 5
- 229960002226 polidocanol Drugs 0.000 claims description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 4
- 239000007995 HEPES buffer Substances 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 14
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 abstract description 8
- 150000001840 cholesterol esters Chemical class 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 8
- 238000002835 absorbance Methods 0.000 abstract description 7
- 102000001554 Hemoglobins Human genes 0.000 abstract description 4
- 108010054147 Hemoglobins Proteins 0.000 abstract description 4
- 235000010323 ascorbic acid Nutrition 0.000 abstract description 4
- 229960005070 ascorbic acid Drugs 0.000 abstract description 4
- 239000011668 ascorbic acid Substances 0.000 abstract description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 101710088194 Dehydrogenase Proteins 0.000 abstract description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 30
- 238000012360 testing method Methods 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 239000004094 surface-active agent Substances 0.000 description 16
- 239000007853 buffer solution Substances 0.000 description 14
- 239000003085 diluting agent Substances 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920001503 Glucan Polymers 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- -1 lipid compounds Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 239000007990 PIPES buffer Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 238000008620 Cholesterol Assay Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000006173 Good's buffer Substances 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- 102000007327 Protamines Human genes 0.000 description 2
- 108010007568 Protamines Proteins 0.000 description 2
- 229920004929 Triton X-114 Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229950008679 protamine sulfate Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- PIIRYSWVJSPXMW-UHFFFAOYSA-N 1-octyl-4-(4-octylphenoxy)benzene Chemical compound C1=CC(CCCCCCCC)=CC=C1OC1=CC=C(CCCCCCCC)C=C1 PIIRYSWVJSPXMW-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical compound [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YEIKGFFXYDKWAJ-UHFFFAOYSA-N ethyl hydrogen sulfate;2-piperazin-1-ylethanol Chemical compound CCOS(O)(=O)=O.OCCN1CCNCC1 YEIKGFFXYDKWAJ-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000013930 proline Nutrition 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000005092 sublimation method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
- G01N21/77—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator
- G01N21/78—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/3103—Atomic absorption analysis
Landscapes
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Plasma & Fusion (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
样本序号 | X | Y | 样本序号 | X | Y |
1 | 4.73 | 4.75 | 26 | 4.73 | 4.75 |
2 | 4.88 | 5.14 | 27 | 4.88 | 5.14 |
3 | 7.31 | 7.73 | 28 | 7.31 | 7.73 |
4 | 6.33 | 7.00 | 29 | 6.33 | 7.00 |
5 | 11.78 | 11.40 | 30 | 11.78 | 11.40 |
6 | 6.38 | 6.54 | 31 | 6.38 | 6.54 |
7 | 3.64 | 4.15 | 32 | 3.64 | 4.15 |
8 | 4.81 | 5.45 | 33 | 4.81 | 5.45 |
9 | 6.65 | 7.42 | 34 | 6.65 | 7.42 |
10 | 3.46 | 4.29 | 35 | 3.46 | 4.29 |
11 | 8.24 | 8.50 | 36 | 8.24 | 8.50 |
12 | 6.12 | 6.41 | 37 | 6.12 | 6.41 |
13 | 1.86 | 2.53 | 38 | 1.86 | 2.53 |
14 | 6.90 | 7.00 | 39 | 6.90 | 7.00 |
15 | 8.09 | 8.54 | 40 | 8.09 | 8.54 |
16 | 8.04 | 8.36 | 41 | 8.04 | 8.36 |
17 | 3.13 | 3.88 | 42 | 3.13 | 3.88 |
18 | 8.14 | 8.06 | 43 | 8.14 | 8.06 |
19 | 5.87 | 6.54 | 44 | 5.87 | 6.54 |
20 | 9.10 | 9.28 | 45 | 9.10 | 9.28 |
21 | 7.34 | 7.57 | 46 | 7.34 | 7.57 |
22 | 11.52 | 12.97 | 47 | 11.52 | 12.97 |
23 | 6.02 | 5.92 | 48 | 6.02 | 5.92 |
24 | 3.62 | 4.22 | 49 | 3.62 | 4.22 |
25 | 6.74 | 8.04 | 50 | 6.74 | 8.04 |
样本号 | 1 | 2 | 3 | 4 | 5 | 6 |
高浓度(活性)血清样本 | 0份 | 1份 | 2份 | 3份 | 4份 | 5份 |
低浓度(活性)样本 | 5份 | 4份 | 3份 | 2份 | 1份 | 0份 |
样本1 | 1 | 2 | 3 | 平均值 | 靶值 | 相对偏差 |
0天 | 6.99 | 6.99 | 7.12 | 7.03 | 7.03 | 0.07% |
2天 | 6.82 | 6.80 | 6.91 | 6.84 | 7.03 | -2.66% |
3天 | 6.72 | 6.70 | 6.55 | 6.66 | 7.03 | -5.31% |
4天 | 6.52 | 6.41 | 6.52 | 6.48 | 7.03 | -7.78% |
6天 | 6.35 | 6.53 | 6.39 | 6.42 | 7.03 | -8.63% |
8天 | 6.32 | 6.46 | 6.37 | 6.38 | 7.03 | -9.21% |
样本2 | 1 | 2 | 3 | 平均值 | 靶值 | 相对偏差 |
0天 | 4.16 | 4.08 | 3.96 | 4.07 | 4.05 | 0.41% |
2天 | 3.87 | 3.95 | 4.02 | 3.95 | 4.05 | -2.55% |
3天 | 3.84 | 3.94 | 3.96 | 3.91 | 4.05 | -3.37% |
4天 | 3.86 | 3.74 | 3.95 | 3.85 | 4.05 | -4.94% |
6天 | 3.72 | 3.63 | 3.76 | 3.70 | 4.05 | -8.56% |
8天 | 3.73 | 3.75 | 3.68 | 3.72 | 4.05 | -8.15% |
样本3 | 1 | 2 | 3 | 平均值 | 靶值 | 相对偏差 |
0月 | 6.88 | 6.87 | 7.11 | 6.95 | 7.03 | -1.09% |
3月 | 7.00 | 6.78 | 6.84 | 6.87 | 7.03 | -2.23% |
6月 | 6.74 | 6.63 | 6.65 | 6.67 | 7.03 | -5.07% |
9月 | 6.57 | 6.61 | 6.50 | 6.56 | 7.03 | -6.69% |
12月 | 6.77 | 6.50 | 6.55 | 6.61 | 7.03 | -6.02% |
15月 | 6.28 | 6.54 | 6.47 | 6.43 | 7.03 | -8.53% |
样本4 | 1 | 2 | 3 | 平均值 | 靶值 | 相对偏差 |
0月 | 4.32 | 4.27 | 4.25 | 4.28 | 4.28 | 0.00% |
3月 | 4.12 | 3.96 | 4.09 | 4.06 | 4.28 | -5.22% |
6月 | 4.07 | 4.09 | 3.87 | 4.01 | 4.28 | -6.31% |
9月 | 3.95 | 4.12 | 4.01 | 4.03 | 4.28 | -5.92% |
12月 | 3.94 | 3.85 | 4.07 | 3.95 | 4.28 | -7.63% |
15月 | 3.83 | 3.97 | 3.90 | 3.90 | 4.28 | -8.88% |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110420447.4A CN113495069B (zh) | 2021-04-19 | 2021-04-19 | 一种总胆固醇检测试剂及检测芯片 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110420447.4A CN113495069B (zh) | 2021-04-19 | 2021-04-19 | 一种总胆固醇检测试剂及检测芯片 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113495069A CN113495069A (zh) | 2021-10-12 |
CN113495069B true CN113495069B (zh) | 2024-04-26 |
Family
ID=77997581
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110420447.4A Active CN113495069B (zh) | 2021-04-19 | 2021-04-19 | 一种总胆固醇检测试剂及检测芯片 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113495069B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621522A (zh) * | 2003-11-28 | 2005-06-01 | 希森美康株式会社 | 胆固醇脱氢酶的稳定方法、含胆固醇脱氢酶的组合物以及胆固醇检测试剂 |
JP2009031102A (ja) * | 2007-07-26 | 2009-02-12 | Panasonic Corp | 試料分析チップ |
CN101374957A (zh) * | 2006-01-20 | 2009-02-25 | 株式会社Jimro | 残粒样脂蛋白中的胆固醇的测定方法 |
JP2009092514A (ja) * | 2007-10-09 | 2009-04-30 | Panasonic Corp | 試料液分析チップ、および試料液の移送制御方法 |
CN101512012A (zh) * | 2006-10-18 | 2009-08-19 | 协和梅迪克斯株式会社 | 小而密低密度脂蛋白中的胆固醇的定量方法 |
CN111032880A (zh) * | 2017-09-01 | 2020-04-17 | 日立化成诊断系统株式会社 | 低密度脂蛋白中的胆固醇的测定方法、测定用试剂和测定用试剂盒 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100062414A1 (en) * | 2007-04-05 | 2010-03-11 | Panasonic Corporation | Sample liquid analytical chip |
-
2021
- 2021-04-19 CN CN202110420447.4A patent/CN113495069B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621522A (zh) * | 2003-11-28 | 2005-06-01 | 希森美康株式会社 | 胆固醇脱氢酶的稳定方法、含胆固醇脱氢酶的组合物以及胆固醇检测试剂 |
CN101374957A (zh) * | 2006-01-20 | 2009-02-25 | 株式会社Jimro | 残粒样脂蛋白中的胆固醇的测定方法 |
CN101512012A (zh) * | 2006-10-18 | 2009-08-19 | 协和梅迪克斯株式会社 | 小而密低密度脂蛋白中的胆固醇的定量方法 |
JP2009031102A (ja) * | 2007-07-26 | 2009-02-12 | Panasonic Corp | 試料分析チップ |
JP2009092514A (ja) * | 2007-10-09 | 2009-04-30 | Panasonic Corp | 試料液分析チップ、および試料液の移送制御方法 |
CN111032880A (zh) * | 2017-09-01 | 2020-04-17 | 日立化成诊断系统株式会社 | 低密度脂蛋白中的胆固醇的测定方法、测定用试剂和测定用试剂盒 |
Non-Patent Citations (1)
Title |
---|
"胆固醇脱氢酶测定血清胆固醇方法的建立";魏明;《检验医学》;第19卷(第5期);第403-405页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113495069A (zh) | 2021-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111707625A (zh) | 一种总胆汁酸测定试剂球的制备方法、试剂球及检测芯片 | |
CN111707631A (zh) | 一种尿素测定试剂球制备方法、试剂球及检测芯片 | |
CA2115276C (en) | Reagent compositions for analytical testing | |
CN102072953B (zh) | 一种稳定的酶法检测唾液酸的方法及试剂盒 | |
CN111948153A (zh) | 一种冻干试剂球、生化分析芯片及血清总钙测定方法 | |
CN108949903B (zh) | 一种甘油三酯测定试剂盒及其测定方法 | |
CN109239059A (zh) | 一种糖化血清蛋白测定试剂盒及其制备方法和应用 | |
CN111808921A (zh) | 一种基于Trinder反应的检测试剂盒及其应用 | |
CN113584125B (zh) | 一种液态稳定的5’-核苷酸酶校准品及检测试剂盒及其应用 | |
CN105954453A (zh) | 一种同时定量检测烟酸、烟酰胺和泛酸的试剂盒 | |
CN105241873A (zh) | 一种脂肪酶检测试剂盒 | |
CN109030671B (zh) | 同时检测pku、cah和g-6pd缺乏症的串联质谱试剂盒及检测方法 | |
CN106868096A (zh) | 一种稳定性强且成本低的己糖激酶法葡萄糖检测试剂 | |
CN105543336B (zh) | 一种稳定、抗干扰能力强的血清磷脂检测试剂及检测方法 | |
CN114200122A (zh) | 一种尿酸检测冻干试剂球、其配置方法及微流控检测芯片 | |
CN113278675B (zh) | 乳酸脱氢酶测定试剂球的制备方法、试剂球及微流控芯片 | |
CN104388530B (zh) | 一种稳定性强的乳酸检测试剂 | |
CN111944872A (zh) | 测定肌酐含量的试剂组合、试剂或试剂盒 | |
CN113281520A (zh) | 血清总蛋白测定试剂球的制备方法、试剂球及微流控芯片 | |
CN113514451B (zh) | 一种血肌酐检测试剂球及血肌酐检测芯片 | |
CN113495069B (zh) | 一种总胆固醇检测试剂及检测芯片 | |
CN102564979A (zh) | 循环酶法测定乙醇浓度的方法及乙醇测定试剂盒 | |
CN113278677B (zh) | α-淀粉酶测定试剂球的制备方法、试剂球及微流控芯片 | |
CN113278676A (zh) | 一种血清钠检测试剂及γ-谷氨酰基转移酶检测试剂 | |
CN101514984B (zh) | 测定血清游离肉碱的试剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: 518000 floors 4-10, building 3, Geya science and Technology Park, mashantou community clock base, Matian street, Guangming New Area, Shenzhen, Guangdong Applicant after: Shenzhen Jinrui Biotechnology Co.,Ltd. Address before: 518106 4-10 / F, building 3, Geya science and Technology Park, mashantou community clock base, Matian street, Guangming New District, Shenzhen City, Guangdong Province Applicant before: GENRUI BIOTECH Inc. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |